These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 15028836)

  • 1. Therapy for irritable bowel syndrome.
    Olden KW
    N Engl J Med; 2004 Mar; 350(12):1261-3; author reply 1261-3. PubMed ID: 15028836
    [No Abstract]   [Full Text] [Related]  

  • 2. Therapy for irritable bowel syndrome.
    Lacy BE
    N Engl J Med; 2004 Mar; 350(12):1261-3; author reply 1261-3. PubMed ID: 15031865
    [No Abstract]   [Full Text] [Related]  

  • 3. Pharmacological treatment of irritable bowel syndrome--from concept to sales.
    Kamm MA
    Eur J Surg Suppl; 2002; (587):10-5. PubMed ID: 16144196
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Irritable bowel syndrome.
    Mertz HR
    N Engl J Med; 2003 Nov; 349(22):2136-46. PubMed ID: 14645642
    [No Abstract]   [Full Text] [Related]  

  • 5. Irritable bowel syndrome.
    Kennedy T; Rubin G; Jones R
    Clin Evid; 2004 Jun; (11):615-25. PubMed ID: 15652025
    [No Abstract]   [Full Text] [Related]  

  • 6. [Role of serotonin in the pathophysiology of the irritable bowel syndrome].
    Moskwa A; Boznańska P
    Wiad Lek; 2007; 60(7-8):371-6. PubMed ID: 18175558
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 5-Hydroxytryptamine effects in the gut: the 3, 4, and 7 receptors.
    Tonini M
    Neurogastroenterol Motil; 2005 Oct; 17(5):637-42. PubMed ID: 16185301
    [No Abstract]   [Full Text] [Related]  

  • 8. Irritable bowel syndrome.
    de Wit N; Rubin G; Jones R
    Clin Evid; 2005 Jun; (13):556-63. PubMed ID: 16135274
    [No Abstract]   [Full Text] [Related]  

  • 9. Gastrointestinal pharmacology: irritable bowel syndrome.
    Bueno L
    Curr Opin Pharmacol; 2005 Dec; 5(6):583-8. PubMed ID: 16188501
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tegaserod for constipation-predominant irritable bowel syndrome.
    Kale-Pradhan PB; Wilhelm SM
    Pharmacotherapy; 2007 Feb; 27(2):267-77. PubMed ID: 17253916
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Irritable bowel syndrome.
    Kennedy T; Rubin G; Jones R
    Clin Evid; 2004 Dec; (12):683-92. PubMed ID: 15865669
    [No Abstract]   [Full Text] [Related]  

  • 12. 3-(Arylsulfonyl)-1-(azacyclyl)-1H-indoles are 5-HT(6) receptor modulators.
    Bernotas RC; Antane S; Shenoy R; Le VD; Chen P; Harrison BL; Robichaud AJ; Zhang GM; Smith D; Schechter LE
    Bioorg Med Chem Lett; 2010 Mar; 20(5):1657-60. PubMed ID: 20138763
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Pharmacoeconomics and outcome research on Irritable Bowel Syndrome review of findings using Tegaserod].
    Ariza JG; Martínez JA
    Rev Gastroenterol Peru; 2006; 26(1):77-9. PubMed ID: 16622489
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of current drug therapies in irritable bowel syndrome: what works and does not work.
    Schoenfeld P
    Gastroenterol Clin North Am; 2005 Jun; 34(2):319-35, viii. PubMed ID: 15862938
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synthesis and 5-HT3 receptor affinity of new quinolinecarboxylic acid derivatives.
    Orjales A; Alonso-Cires L; López-Tudanca PL; Tapia I; Labeaga L; Mosquera R
    Drug Des Discov; 2000; 16(4):271-9. PubMed ID: 10807033
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New esters of 4-amino-5-chloro-2-methoxybenzoic acid as potent agonists and antagonists for 5-HT4 receptors.
    Yang D; Soulier JL; Sicsic S; Mathé-Allainmat M; Brémont B; Croci T; Cardamone R; Aureggi G; Langlois M
    J Med Chem; 1997 Feb; 40(4):608-21. PubMed ID: 9046352
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tegaserod and other serotonergic agents: what is the evidence?
    Chey WD
    Rev Gastroenterol Disord; 2003; 3 Suppl 2():S35-40. PubMed ID: 12776001
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Options for patients with irritable bowel syndrome: contrasting traditional and novel serotonergic therapies.
    Johanson JF
    Neurogastroenterol Motil; 2004 Dec; 16(6):701-11. PubMed ID: 15601419
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Drug therapy options for patients with irritable bowel syndrome.
    Talley NJ
    Am J Manag Care; 2001 Jul; 7(8 Suppl):S261-7. PubMed ID: 11474911
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intestinal prokinesia by two esters of 4-amino-5-chloro-2- methoxybenzoic acid: involvement of 5-hydroxytryptamine-4 receptors and dissociation from cardiac effects in vivo.
    Crema F; Modini C; Croci T; Langlois M; de Ponti F
    J Pharmacol Exp Ther; 1999 Mar; 288(3):1045-52. PubMed ID: 10027842
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.